Glenmark Pharmaceuticals ltd — Capital/Financing Update 2022

Jun 28, 2022

==> picture [16 x 10] intentionally omitted <==

==> picture [17 x 10] intentionally omitted <==

==> picture [140 x 42] intentionally omitted <==

June 28, 2022

To, To, Dy. General Manager The Manager – Listing, Department of Corporate Services, The National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumbai – 400 001. Bandra (E), Mumbai – 400 051.

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sir,

Sub: Glenmark Pharmaceuticals Inc., USA continues to expand its Over‐The‐Counter (OTC) Portfolio with the acquisition of approved ANDAs from Wockhardt Limited

With reference to the subject mentioned above, kindly find attached media release which is self‐explanatory.

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For Glenmark Pharmaceuticals Limited

Digitally signed by HARISH HARISH VINAYAK KUBER VINAYAK KUBER Date: 2022.06.28 08:32:45 +05'30' Harish Kuber

Company Secretary & Compliance Officer

Encl: as above

Glenmark Pharmaceuticals Ltd. Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099 T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: www.glenmarkpharma.com Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

==> picture [561 x 76] intentionally omitted <==

Press Release

For Immediate Distribution

Glenmark Pharmaceuticals Inc., USA continues to expand its Over-The-Counter (OTC) Portfolio with the acquisition of approved ANDAs from Wockhardt Limited

Mumbai, India; New Jersey; USA; June 28 2022: Glenmark Pharmaceuticals Ltd, an innovation-driven, global pharmaceutical company, announced that its fully owned subsidiary Glenmark Pharmaceuticals Inc., USA (Glenmark) has acquired the approved Abbreviated New Drug Applications (ANDAs) for Famotidine Tablets USP, 10 mg and 20 mg (OTC), Cetirizine Hydrochloride Tablets USP, 5 mg and 10 mg (OTC), Lansoprazole DelayedRelease Capsules USP, 15 mg (OTC) and Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% (OTC) in the United States from Wockhardt Limited.

Sanjeev Krishan, President of Glenmark Pharmaceuticals Inc., USA, commented “The over-the-counter market has long been an important segment of Glenmark’s portfolio around the world. Our acquisition of these ANDAs represents the continued expansion of our business into the OTC market here in the United States and our commitment to ensuring patients have access to high quality, affordable medicines.”

Glenmark’s current portfolio consists of 175 products authorized for distribution in the U.S. marketplace and 48 ANDAs pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

------End------

About Glenmark Pharmaceuticals Ltd.

Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is an innovation-driven global pharmaceutical company with a presence across Specialty, Generics and OTC businesses. It focuses on the key therapeutic areas of respiratory, dermatology and oncology. The company has 10 world-class manufacturing facilities spread across 4 continents and operations in over 80 countries. Glenmark is ranked among the world’s top 100 biopharmaceutical companies (Top 100 Companies Ranked by Pharmaceutical Sales, 2020, by In Vivo/Scrip 100) and among the world’s top 50 companies in the off-patent sector (Top 50 Generics and Biosimilars Companies ranked by Sales, 2020, by Generics Bulletin/In Vivo). The company was listed on the Dow Jones Sustainability Index (DJSI), one of the world’s most respected and widely accepted sustainability benchmarks, under the category of emerging markets (2021) for the fourth consecutive year in a row. For more information, visit www.glenmarkpharma.com.

Follow us on Social Media: LinkedIn (Glenmark Pharmaceuticals) and Instagram (glenmark_pharma)

For more information, please contact

Udaykumar Murthy DGM, Corporate Communications +91 9960377617 | corpcomm@glenmarkpharma.com

==> picture [560 x 28] intentionally omitted <==